Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 11Pemetrexed 10pembrolizumab 9Nivolumab 3LMB-100 3budigalimab 2belinostat 2amatuximab 2Paclitaxel 2Docetaxel 2Dexamethasone 2Cyclophosphamide 2Carboplatin 2Calcium Dobesilate 2venetoclax 1trametinib 1tislelizumab 1tazemetostat 1talazoparib 1spartalizumab 1sodium thiosulfate 1sargramostim 1ruxolitinib 1rovalpituzumab tesirine 1olaparib 1obinutuzumab 1naptumomab estafenatox 1irinotecan sucrosofate 1fludarabine 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Mesothelioma × OSI 930 × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡